#Coronavirus Disease Research #References (by AMEDEO, June 14 '25)

 

Antiviral Res

1. CHANG CW, Oswal N, Murugan M, Goldgirsh K, et al
   A novel cellular tool for screening human pan-coronavirus antivirals.
   Antiviral Res. 2025 Jun 10:106212. doi: 10.1016/j.antiviral.2025.106212.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. LEE R, Kim N, Kim WB, Im KI, et al
   Effectiveness and safety of Autologous Virus-Specific T Cell Therapy for Persistent COVID-19 in People with Immunocompromise: A Clinical Trial Study.
   Clin Infect Dis. 2025 Jun 10:ciaf302. doi: 10.1093.
   PubMed         Abstract available
   
   
3. SUDNIK P, Walsh EE, Branche AR, Islam M, et al
   Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with RSV.
   Clin Infect Dis. 2025 Jun 12:ciaf310. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. WEE LE, Ho RWL, Lim JT, Chiew CJ, et al
   Long-term multi-systemic sequelae post-hospitalization for Omicron COVID-19 versus influenza: a retrospective cohort study.
   Int J Infect Dis. 2025 Jun 9:107946. doi: 10.1016/j.ijid.2025.107946.
   PubMed         Abstract available
   
   

   
   J Infect

5. BUTLER CC, Hobbs FDR, Little P, Richards D, et al
   Ivermectin and COVID-19.
   J Infect. 2025 Jun 8:106530. doi: 10.1016/j.jinf.2025.106530.
   PubMed        
   
   

   
   J Med Virol

6. PEREZ-COZAR F, Cal-Sabater P, Rybakowska P, Arribas-Rodriguez E, et al
   High-Dimensional Immunophenotyping of Post-COVID-19 and Post-Influenza Patients Reveals Persistent and Specific Immune Signatures After Acute Respiratory Infection.
   J Med Virol. 2025;97:e70435.
   PubMed         Abstract available
   
   
7. FERNANDEZ-DE-LAS-PENAS C, Arendt-Nielsen L, Gil-Crujera A, Gomez-Sanchez SM, et al
   ACE1 rs1799752 Polymorphism Is not Associated With the Presence of Post-COVID-19 Condition.
   J Med Virol. 2025;97:e70438.
   PubMed        
   
   

   
   J Virol

8. COTTIGNIES-CALAMARTE A, Marteau F, He F, Belouzard S, et al
   Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response.
   J Virol. 2025 Jun 12:e0039425. doi: 10.1128/jvi.00394.
   PubMed         Abstract available
   
   
9. LIU M, Aryal B, Niu X, Wang Q, et al
   Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.
   J Virol. 2025 Jun 12:e0045125. doi: 10.1128/jvi.00451.
   PubMed         Abstract available
   
   
10. MORGAN AL, Vu MN, Zhou Y, Lokugamage KG, et al
    The furin cleavage site is required for pathogenesis, but not transmission, of SARS-CoV-2.
    J Virol. 2025 Jun 10:e0046725. doi: 10.1128/jvi.00467.
    PubMed         Abstract available
    
    
11. FOSTER CSP, Walker GJ, Jean T, Wong M, et al
    Long-term serial passaging of SARS-CoV-2 reveals signatures of convergent evolution.
    J Virol. 2025 Jun 9:e0036325. doi: 10.1128/jvi.00363.
    PubMed         Abstract available
    
    
12. LOKUGAMAGE KG, Zhou Y, Alvarado RE, Plante JA, et al
    Convergent evolution in nucleocapsid facilitated SARS-CoV-2 adaptation for human infection.
    J Virol. 2025 Jun 12:e0209124. doi: 10.1128/jvi.02091.
    PubMed         Abstract available
    
    
13. LI C, Shi Y, Xie C, Duan K, et al
    GSDMD and GSDME exhibit distinct roles in enteric coronavirus PDCoV-induced pyroptosis and inflammatory responses.
    J Virol. 2025 Jun 12:e0187624. doi: 10.1128/jvi.01876.
    PubMed         Abstract available
    
    
14. HARRIS C, Kapingidza AB, San JE, Christopher J, et al
    Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes.
    J Virol. 2025 Jun 13:e0046525. doi: 10.1128/jvi.00465.
    PubMed         Abstract available
    
    

    
    JAMA

15. GOSTIN LO, Reiss D, Offit PA
    Changed Recommendations for COVID-19 Vaccines for Children and Pregnant Women: A Failure of Process, Policy, and Science.
    JAMA. 2025 Jun 13. doi: 10.1001/jama.2025.10658.
    PubMed        
    
    
16. ZETTLER PJ, Cha S, Despres S, Lurie P, et al
    FDA Review of Novavax's COVID-19 Vaccine-Regulatory Integrity and Deviations From Standard Practice.
    JAMA. 2025 Jun 9. doi: 10.1001/jama.2025.9898.
    PubMed        
    
    

    
    Lancet Infect Dis

17. URIU K, Okumura K, Uwamino Y, Chen L, et al
    Virological characteristics of the SARS-CoV-2 NB.1.8.1 variant.
    Lancet Infect Dis. 2025 Jun 6:S1473-3099(25)00356.
    PubMed        
    
    
18. GUO C, Yu Y, Liu J, Jian F, et al
    Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1.
    Lancet Infect Dis. 2025 Jun 5:S1473-3099(25)00308.
    PubMed        
    
    

    
    N Engl J Med

19. MCINTYRE L, Fergusson D, McArdle T, English S, et al
    A Crossover Trial of Hospital-Wide Lactated Ringer's Solution versus Normal Saline.
    N Engl J Med. 2025 Jun 12. doi: 10.1056/NEJMoa2416761.
    PubMed         Abstract available
    
    

    
    Zhonghua Jie He He Hu Xi Za Zhi

20. CHEN T, Xu ZJ
    [Recomment of the correctly understand and standardize the use of terms and concepts related to interstitial lung disease].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:589-591.
    PubMed         Abstract available